{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:02:32Z","timestamp":1793833352685,"version":"4.6.1"},"reference-count":397,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>CRISPR\u2013Cas genome-editing technologies have emerged as powerful tools for precise DNA and RNA modulation, offering promising therapeutic strategies for neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). This review critically evaluates current CRISPR\/Cas applications in neurodegeneration, with emphasis on mechanistic insights, therapeutic outcomes, and translational feasibility. Preclinical and early translational studies demonstrate that CRISPR\u2013Cas platforms can correct pathogenic mutations, suppress toxic gene expression, and restore neuronal function. Advanced modalities, including base and prime editing, CRISPRi\/a, and RNA-targeting Cas systems, improve precision and reduce genomic damage, which is particularly advantageous in post-mitotic neurons. Emerging CRISPR-based diagnostics (e.g., SHERLOCK and DETECTR), AI-assisted sgRNA design, and machine-learning approaches for predicting off-target effects further enhance the safety, stratification, and monitoring of CRISPR therapeutics. In parallel, patient-derived brain organoids and assembloids provide scalable human-relevant platforms for mechanistic studies and preclinical validation. Despite this progress, major challenges remain, including efficient delivery across the blood\u2013brain barrier, immune responses, long-term safety, and ethical and regulatory considerations. Overall, CRISPR\u2013Cas technologies hold strong potential as disease-modifying interventions for neurodegenerative disorders, provided that advances in delivery systems, artificial intelligence integration, and regulatory oversight continue to evolve toward clinical translation.<\/jats:p>","DOI":"10.3389\/fneur.2025.1737468","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:07:48Z","timestamp":1769519268000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["CRISPR\u2013Cas technologies in neurodegenerative disorders: mechanistic insights, therapeutic potential, and translational challenges"],"prefix":"10.3389","volume":"16","author":[{"given":"Raya Kh.","family":"Yashooa","sequence":"first","affiliation":[{"name":"Department of Biology, College of Education for Pure Sciences, University of Al-Hamdaniya","place":["Mosul, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari Q.","family":"Nabi","sequence":"additional","affiliation":[{"name":"Department of Biology, College of Science, Salahaddin University-Erbil","place":["Erbil, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukur Wasman","family":"Smail","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Cihan University-Erbil","place":["Erbil, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarkar Sardar","family":"Azeez","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Technology, Soran Technical College, Erbil Polytechnic University","place":["Erbil, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wissam Albeer","family":"Nooh","sequence":"additional","affiliation":[{"name":"Department of Biology, College of Education for Pure Sciences, University of Al-Hamdaniya","place":["Mosul, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhad A.","family":"Mustafa","sequence":"additional","affiliation":[{"name":"General Directorate of Scientific Research Center, Salahaddin University-Erbil","place":["Erbil, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abd Al-Bar","family":"Al-Farha","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Food Sciences, Technical Agricultural College-Mosul, Northern Technical University","place":["Mosul, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazzareno","family":"Capitanio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Foggia","place":["Foggia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudhir Sabir","family":"Shekha","sequence":"additional","affiliation":[{"name":"Department of Biology, College of Science, Salahaddin University-Erbil","place":["Erbil, Iraq"]},{"name":"Department of Medical Cell Biology, Uppsala University","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1582-4934.2010.01010.x","article-title":"Basic mechanisms of neurodegeneration: a critical update","volume":"14","author":"Jellinger","year":"2010","journal-title":"J Cell Mol Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"18","author":"Feigin","year":"2019","journal-title":"Lancet Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/ijms23031851","article-title":"Review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics","volume":"23","author":"Lamptey","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1596\/978-1-4648-0426-7_ch5","article-title":"Neurological Disorders","volume-title":"Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, Third Edition (Volume 4)","author":"Thakur","year":"2016"},{"key":"B5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/pathophysiology32030043","article-title":"Current evidence on the involvement of Rage\u2013Diaph1 signaling in the pathology and treatment of neurodegenerative diseases\u2014an overview","volume":"32","author":"Juranek","year":"2025","journal-title":"Pathophysiology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.18773\/austprescr.2024.021","article-title":"New and emerging drug therapies for Alzheimer disease","volume":"47","author":"Waite","year":"2024","journal-title":"Aust Prescr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"100195","DOI":"10.1016\/j.tjpad.2025.100195","article-title":"The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis","volume":"12","author":"Hsu","year":"2025","journal-title":"J Prev Alzheimers Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12264-010-0302-z","article-title":"Treatment strategies for Parkinson's disease","volume":"26","author":"Yuan","year":"2010","journal-title":"Neurosci Bull."},{"key":"B9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/biomedicines10020371","article-title":"Emerging therapeutic strategies for Parkinson's disease and future prospects: a 2021 update","volume":"10","author":"Gouda","year":"2022","journal-title":"Biomedicines."},{"key":"B10","doi-asserted-by":"publisher","first-page":"6220","DOI":"10.3390\/ijms26136220","article-title":"Update on the symptomatic treatment of Huntington's disease: from pathophysiology to clinical practice","volume":"26","author":"Olmedo-Saura","year":"2025","journal-title":"Int J Mol Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11910-024-01345-y","article-title":"Huntington's disease: latest frontiers in therapeutics","volume":"24","author":"Saade","year":"2024","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s42466-019-0039-8","article-title":"Molecular mechanisms of proteinopathies across neurodegenerative disease: a review","volume":"1","author":"Marsh","year":"2019","journal-title":"Neurol Res Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrd.2015.21","article-title":"From blood\u2013brain barrier to blood\u2013brain interface: new opportunities for cns drug delivery","volume":"15","author":"Banks","year":"2016","journal-title":"Nat Rev Drug Discov."},{"key":"B14","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3233\/JAD-2011-110368","article-title":"The role of the blood brain barrier in neurodegenerative disorders and their treatment","volume":"24","author":"Palmer","year":"2011","journal-title":"J Alzheimers Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cell.2021.10.029","article-title":"Central nervous system regeneration","volume":"185","author":"Varadarajan","year":"2022","journal-title":"Cell."},{"key":"B16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.17179\/excli2023-6155","article-title":"Crispr\/Cas9 genome editing for neurodegenerative diseases","volume":"22","author":"Nojadeh","year":"2023","journal-title":"EXCLI J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/B978-0-12-381328-2.00014-6","article-title":"Genetics and neuropathology of Huntington's disease","volume":"98","author":"Reiner","year":"2011","journal-title":"Int Rev Neurobiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1002270","DOI":"10.1371\/journal.pmed.1002270","article-title":"App, Psen1, and Psen2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases","volume":"14","author":"Lanoisel\u00e9e","year":"2017","journal-title":"PLoS Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13024-016-0097-0","article-title":"Resequencing analysis of five mendelian genes and the top genes from genome-wide association studies in Parkinson's disease","volume":"11","author":"Benitez","year":"2016","journal-title":"Mol Neurodegener."},{"key":"B20","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"Programmable Dual-Rna\u2013Guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1509924","DOI":"10.3389\/fgeed.2024.1509924","article-title":"Advances in Crispr-Cas technology and its applications: revolutionising precision medicine","volume":"6","author":"Azeez","year":"2024","journal-title":"Front Genome Ed."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41598-018-37949-x","article-title":"Gene silencing based on Rna-guided catalytically inactive Cas9 (Dcas9): a new tool for genetic engineering in leptospira","volume":"9","author":"Fernandes","year":"2019","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"6240","DOI":"10.3390\/ijms21176240","article-title":"Crispr-Cas9 DNA base-editing and prime-editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"0041","DOI":"10.34133\/bdr.0041","article-title":"Crispr\u2013Cas13: pioneering Rna editing for nucleic acid therapeutics","volume":"6","author":"Zhu","year":"2024","journal-title":"BioDesign Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s42003-018-0054-2","article-title":"Martin A, Harris RS, Gordon WR. Increasing Cas9-mediated homology-directed repair efficiency through covalent tethering of DNA repair template","volume":"1","author":"Aird","year":"2018","journal-title":"Commun Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/jnen\/nly040","article-title":"Damage response and repair, DNA methylation, and cell death in human neurons and experimental animal neurons are different","volume":"77","author":"Martin","year":"2018","journal-title":"J Neuropathol Exp Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","article-title":"Crispr gene therapy: applications, limitations, and implications for the future","volume":"10","author":"Uddin","year":"2020","journal-title":"Front Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.molcel.2014.03.011","article-title":"Crispr-Cas systems: prokaryotes upgrade to adaptive immunity","volume":"54","author":"Barrangou","year":"2014","journal-title":"Mol Cell."},{"key":"B29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrmicro.2015.14","article-title":"Crispr\u2013Cas adaptation: insights into the mechanism of action","volume":"14","author":"Amitai","year":"2016","journal-title":"Nat Rev Microbiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"a003657","DOI":"10.1101\/cshperspect.a003657","article-title":"Rna in defense: Crisprs protect prokaryotes against mobile genetic elements","volume":"4","author":"Jore","year":"2012","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrmicro3569","article-title":"An updated evolutionary classification of Crispr\u2013Cas systems","volume":"13","author":"Makarova","year":"2015","journal-title":"Nat Rev Microbiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"14473","DOI":"10.1074\/jbc.REV120.007034","article-title":"Chemistry of class 1 Crispr-Cas effectors: binding, editing, and regulation","volume":"295","author":"Liu","year":"2020","journal-title":"J Biol Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"100013","DOI":"10.1016\/j.ggedit.2022.100013","article-title":"Genome editing technology and applications with the type I Crispr system","volume":"3","author":"Yoshimi","year":"2022","journal-title":"Gene Genome Ed."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1134\/S0006297921100114","article-title":"Type Iii Crispr-Cas systems: deciphering the most complex prokaryotic immune system","volume":"86","author":"Kolesnik","year":"2021","journal-title":"Biochemistry."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1093\/nar\/gkz1197","article-title":"Type Iv Crispr\u2013Cas systems are highly diverse and involved in competition between plasmids","volume":"48","author":"Pinilla-Redondo","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1021\/acschembio.7b00800","article-title":"Diverse class 2 Crispr-Cas effector proteins for genome engineering applications","volume":"13","author":"Pyzocha","year":"2018","journal-title":"ACS Chem Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of Crispr-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell."},{"key":"B38","doi-asserted-by":"publisher","first-page":"726","DOI":"10.4161\/rna.24321","article-title":"The Tracrrna and Cas9 families of type Ii Crispr-Cas immunity systems","volume":"10","author":"Chylinski","year":"2013","journal-title":"RNA Biol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.aav7271","article-title":"Functionally dverse type V Crispr-Cas systems","volume":"363","author":"Yan","year":"2019","journal-title":"Science."},{"key":"B40","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jmb.2018.06.029","article-title":"Molecular mechanisms of Rna targeting by Cas13-containing type Vi Crispr\u2013Cas systems","volume":"431","author":"O'Connell","year":"2019","journal-title":"J Mol Biol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","article-title":"The next generation of Crispr\u2013Cas technologies and applications","volume":"20","author":"Pickar-Oliver","year":"2019","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41467-018-04252-2","article-title":"The Crispr tool kit for genome editing and beyond","volume":"9","author":"Adli","year":"2018","journal-title":"Nat Commun."},{"key":"B43","doi-asserted-by":"publisher","first-page":"E2579","DOI":"10.1073\/pnas.1208507109","article-title":"Cas9\u2013Crrna ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria","volume":"109","author":"Gasiunas","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/BTT.S326422","article-title":"Mechanism and applications of Crispr\/Cas-9-mediated genome editing","volume":"15","author":"Asmamaw","year":"2021","journal-title":"Biol Targets Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cell.2014.02.001","article-title":"Crystal structure of Cas9 in complex with guide Rna and target DNA","volume":"156","author":"Nishimasu","year":"2014","journal-title":"Cell."},{"key":"B46","doi-asserted-by":"publisher","first-page":"841","DOI":"10.4161\/rna.24203","article-title":"Crrna and Tracrrna guide Cas9-mediated DNA interference in Streptococcus thermophilus","volume":"10","author":"Karvelis","year":"2013"},{"key":"B47","doi-asserted-by":"publisher","first-page":"341","DOI":"10.5483\/BMBRep.2020.53.7.070","article-title":"Development of Crispr\/Cas9 system for targeted DNA modifications and recent improvements in modification efficiency and specificity","volume":"53","author":"Shin","year":"2020","journal-title":"BMB Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"6461","DOI":"10.3390\/ijms21186461","article-title":"Methods favoring homology-directed repair choice in response to Crispr\/Cas9 induced-double strand breaks","volume":"21","author":"Yang","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"102344","DOI":"10.1016\/j.omtn.2024.102344","article-title":"Crispr-Cas9-mediated homology-directed repair for precise gene editing","volume":"35","author":"Liao","year":"2024","journal-title":"Mol Ther Nucleic Acids."},{"key":"B50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"Guide-Seq enables genome-wide profiling of off-target cleavage by Crispr-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat Biotechnol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nmeth.2857","article-title":"Efficient genome modification by Crispr-Cas9 nickase with minimal off-target effects","volume":"11","author":"Shen","year":"2014","journal-title":"Nat Methods."},{"key":"B52","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1038\/s41467-022-32157-8","article-title":"Cytosine base editing systems with minimized off-target effect and molecular size","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41587-022-01533-6","article-title":"Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity","volume":"41","author":"Neugebauer","year":"2023","journal-title":"Nat Biotechnol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature."},{"key":"B55","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","article-title":"Base editing: advances and therapeutic opportunities","volume":"19","author":"Porto","year":"2020","journal-title":"Nat Rev Drug Discov."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1002\/jcp.30064","article-title":"Crispr\/Cas gene therapy","volume":"236","author":"Zhang","year":"2021","journal-title":"J Cell Physiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jamaneurol.2016.3388","article-title":"Genome editing of monogenic neuromuscular diseases: a systematic review","volume":"73","author":"Long","year":"2016","journal-title":"JAMA Neurol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of a\u2022 T to G\u2022 C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature."},{"key":"B59","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature."},{"key":"B60","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat Rev Genet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nature24049","article-title":"Rna targeting with Crispr-Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature."},{"key":"B62","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bj.2019.10.005","article-title":"Crispr-Cas12a: functional overview and applications","volume":"43","author":"Paul","year":"2020","journal-title":"Biomed J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ymeth.2021.02.018","article-title":"Crispr-Cas12-based nucleic acids detection systems","volume":"203","author":"Leung","year":"2022","journal-title":"Methods."},{"key":"B64","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1126\/science.aav4294","article-title":"Programmed DNA destruction by miniature Crispr-Cas14 enzymes","volume":"362","author":"Harrington","year":"2018","journal-title":"Science."},{"key":"B65","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1016\/j.molcel.2021.08.008","article-title":"Engineered miniature Crispr-Cas system for mammalian genome regulation and editing","volume":"81","author":"Xu","year":"2021","journal-title":"Mol Cell."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"Rna editing with Crispr-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science."},{"key":"B67","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1126\/science.aax9181","article-title":"Rna-guided DNA insertion with Crispr-associated transposases","volume":"365","author":"Strecker","year":"2019","journal-title":"Science."},{"key":"B68","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1089\/crispr.2020.0064","article-title":"Crispr-Cas Activators for engineering gene expression in higher eukaryotes","volume":"3","author":"Casas-Mollano","year":"2020","journal-title":"CRISPR J."},{"key":"B69","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13024-020-00402-7","article-title":"Crispr interference and its applications","volume":"180","author":"Ghavami","year":"2021","journal-title":"Prog Mol Biol Transl Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"201129","DOI":"10.1016\/j.humgen.2022.201129","article-title":"The Mir-146a-5p and Mir-125b-5p levels as biomarkers for early prediction of Alzheimer's disease","volume":"34","author":"Yashooa","year":"2022","journal-title":"Hum Gene."},{"key":"B71","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3390\/ijms26020626","article-title":"Mitochondrial micrornas: key drivers in unraveling neurodegenerative diseases","volume":"26","author":"Yashooa","year":"2025","journal-title":"Int J Mol Sci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"a006239","DOI":"10.1101\/cshperspect.a006239","article-title":"Epidemiology of Alzheimer disease","volume":"2","author":"Mayeux","year":"2012","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"14","DOI":"10.14715\/cmb\/2022.68.9.2","article-title":"Telomerase reverse transcriptase and telomerase Rna component gene expression as a novel biomarkers for Alzheimer's disease","volume":"68","author":"Yashooa","year":"2022","journal-title":"Cell Mol Biol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nrneurol.2011.2","article-title":"Epidemiology of Alzheimer disease","volume":"7","author":"Reitz","year":"2011","journal-title":"Nat Rev Neurol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000505741","article-title":"Global mapping of interventions to improve quality of life of patients with Alzheimer's disease during 1990\u20132018","volume":"48","author":"Hoang","year":"2020","journal-title":"Dement Geriatr Cogn Disord."},{"key":"B76","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-030-05542-4_5","article-title":"Genetic risk factors for Alzheimer disease: emerging roles of microglia in disease pathomechanisms","volume":"1118","author":"Takatori","year":"2019","journal-title":"Adv Exp Med Biol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/hmg\/ddt451","article-title":"Altered Cpg methylation in sporadic Alzheimer's disease is associated with App and Mapt dysregulation","volume":"23","author":"Iwata","year":"2014","journal-title":"Hum Mol Genet."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e31039","DOI":"10.1371\/journal.pone.0031039","article-title":"Rare variants in App, Psen1 and Psen2 increase risk for Ad in late-onset Alzheimer's disease families","volume":"7","author":"Cruchaga","year":"2012","journal-title":"PLoS ONE."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.3390\/ijms21051666","article-title":"Contributions of DNA damage to Alzheimer's disease","volume":"21","author":"Lin","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2047-9158-1-24","article-title":"Advances in the pathogenesis of Alzheimer's disease: focusing on tau-mediated neurodegeneration","volume":"1","author":"Duan","year":"2012","journal-title":"Transl Neurodegener."},{"key":"B81","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1582-4934.2008.00225.x","article-title":"Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention","volume":"12","author":"Iqbal","year":"2008","journal-title":"J Cell Mol Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3233\/JAD-160612","article-title":"Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer's disease neurons","volume":"57","author":"Rajmohan","year":"2017","journal-title":"J Alzheimers Dis."},{"key":"B83","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.bbadis.2004.09.008","article-title":"Tau pathology in Alzheimer disease and other tauopathies","volume":"1739","author":"Iqbal","year":"2005","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B84","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer's disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","article-title":"Neuroinflammation in Alzheimer's disease: current evidence and future directions","volume":"12","author":"Calsolaro","year":"2016","journal-title":"Alzheimers Dement."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-2010-1414","article-title":"Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation","volume":"21","author":"Hensley","year":"2010","journal-title":"J Alzheimers Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01616412.2025.2520983","article-title":"Kenpaullone Attenuates Amyloid-Beta deposition and neuroinflammation, improving memory in a 5xfad mouse model of Alzheimer's disease","volume":"48","author":"Smail","year":"2025","journal-title":"Neurol Res."},{"key":"B88","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40120-020-00218-z","article-title":"Crispr-Cas9: a promising genome editing therapeutic tool for Alzheimer's Disease\u2014a narrative review","volume":"9","author":"Barman","year":"2020","journal-title":"Neurol Ther."},{"key":"B89","doi-asserted-by":"publisher","first-page":"803894","DOI":"10.3389\/fnins.2021.803894","article-title":"Application of Crispr\/Cas9 in Alzheimer's disease","volume":"15","author":"Lu","year":"2021","journal-title":"Front Neurosci."},{"key":"B90","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.omtn.2018.03.007","article-title":"Crispr\/Cas9 mediated disruption of the Swedish App Allele as a therapeutic approach for early-onset Alzheimer's disease","volume":"11","author":"Gy\u00f6rgy","year":"2018","journal-title":"Mol Ther Nucleic Acids."},{"key":"B91","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41467-018-07971-8","article-title":"Crispr\/Cas9 editing of App C-terminus attenuates B-cleavage and promotes A-cleavage","volume":"10","author":"Sun","year":"2019","journal-title":"Nat Commun."},{"key":"B92","doi-asserted-by":"publisher","first-page":"104785","DOI":"10.1016\/j.nbd.2020.104785","article-title":"Novel Presenilin 1 and 2 double knock-out cell line for in vitro validation of Psen1 and Psen2 mutations","volume":"138","author":"Pimenova","year":"2020","journal-title":"Neurobiol Dis."},{"key":"B93","doi-asserted-by":"publisher","first-page":"E476","DOI":"10.1073\/pnas.1618657114","article-title":"Analysis of 138 pathogenic mutations in Presenilin-1 on the in vitro production of A\u03b242 and A\u03b240 peptides by \u0393-secretase","volume":"114","author":"Sun","year":"2017","journal-title":"Proc Natl Acad Sci USA."},{"key":"B94","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.omtn.2022.03.022","article-title":"Crispr-Cas9 treatment partially restores amyloid-B 42\/40 in human fibroblasts with the Alzheimer's disease Psen1 M146l mutation","volume":"28","author":"Konstantinidis","year":"2022","journal-title":"Mol Ther Nucleic Acids."},{"key":"B95","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3233\/JAD-190223","article-title":"Upregulation of thioredoxin-interacting protein in brain of amyloid-B protein Precursor\/Presenilin 1 transgenic mice and amyloid-B treated neuronal cells","volume":"72","author":"Wang","year":"2019","journal-title":"J Alzheimers Dis."},{"key":"B96","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.omtn.2021.02.032","article-title":"Base editing strategy for insertion of the A673t mutation in the App gene to prevent the development of Ad in vitro","volume":"24","author":"Guyon","year":"2021","journal-title":"Mol Ther Nucleic Acids."},{"key":"B97","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fncel.2019.00137","article-title":"The neuroprotection of Kibra in promoting neuron survival and against amyloid B-induced apoptosis","volume":"13","author":"Song","year":"2019","journal-title":"Front Cell Neurosci."},{"key":"B98","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/crispr.2021.0085","article-title":"Insertion of the icelandic mutation (A673t) by prime editing: a potential preventive treatment for familial and sporadic Alzheimer's disease","volume":"5","author":"Tremblay","year":"2022","journal-title":"CRISPR J."},{"key":"B99","doi-asserted-by":"publisher","first-page":"102372","DOI":"10.1016\/j.stemcr.2024.11.002","article-title":"Optimized prime editing of the Alzheimer's disease-associated Apoe4 mutation","volume":"20","author":"Rottner","year":"2025","journal-title":"Stem Cell Rep."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-020-00399-z","article-title":"T'Syen D, Perez-Benito L, Theys T, Holt MG, De Strooper B. Modeling the B-Secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer's disease","volume":"15","author":"Serneels","year":"2020","journal-title":"Mol Neurodegener"},{"key":"B101","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41422-021-00582-x","article-title":"An App Knock-in Rat model for Alzheimer's disease exhibiting A\u03b2 and Tau pathologies, neuronal death and cognitive impairments","volume":"32","author":"Pang","year":"2022","journal-title":"Cell Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"e12787","DOI":"10.1111\/jpi.12787","article-title":"Activation of melatonin receptor 1 by Crispr-Cas9 activator ameliorates cognitive deficits in an Alzheimer's disease mouse model","volume":"72","author":"Park","year":"2022","journal-title":"J Pineal Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41593-019-0352-0","article-title":"In vivo neuronal gene editing via Crispr-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease","volume":"22","author":"Park","year":"2019","journal-title":"Nat Neurosci."},{"key":"B104","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1016\/j.ymthe.2021.09.002","article-title":"In vivo somatic cell base editing and prime editing","volume":"29","author":"Newby","year":"2021","journal-title":"Mol Ther."},{"key":"B105","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40035-024-00415-y","article-title":"Crispr base editing-mediated correction of a tau mutation rescues cognitive decline in a mouse model of tauopathy","volume":"13","author":"Gee","year":"2024","journal-title":"Transl Neurodegener."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/s41591-024-03466-w","article-title":"In vivo base editing extends lifespan of a humanized mouse model of prion disease","volume":"31","author":"An","year":"2025","journal-title":"Nat Med."},{"key":"B107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-020-00402-7","article-title":"The Alzheimer's disease-associated protective Plc\u03b32-P522r variant promotes immune functions","volume":"15","author":"Takalo","year":"2020","journal-title":"Mol Neurodegener."},{"key":"B108","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41398-018-0319-z","article-title":"Integrative system biology analyses of Crispr-Edited Ipsc-derived neurons and human brains reveal deficiencies of presynaptic signaling in Ftld and Psp","volume":"8","author":"Jiang","year":"2018","journal-title":"Transl Psychiatry."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-018-0265-5","article-title":"Ipsc-derived familial Alzheimer's Psen2 N141i cholinergic neurons exhibit mutation-dependent molecular pathology corrected by insulin signaling","volume":"13","author":"Moreno","year":"2018","journal-title":"Mol Neurodegener."},{"key":"B110","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nature17664","article-title":"Efficient introduction of specific homozygous and heterozygous mutations using Crispr\/Cas9","volume":"533","author":"Paquet","year":"2016","journal-title":"Nature."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-017-0475-z","article-title":"Crispr\/Cas9-correctable mutation-related molecular and physiological phenotypes in Ipsc-derived Alzheimer's Psen2 N141i neurons","volume":"5","author":"Ortiz-Virumbrales","year":"2017","journal-title":"Acta Neuropathol Commun."},{"key":"B112","doi-asserted-by":"publisher","first-page":"102552","DOI":"10.1016\/j.scr.2021.102552","article-title":"Generation of gene edited Hipsc from familial Alzheimer's disease patient carrying N141i missense mutation in presenilin 2","volume":"56","author":"Marei","year":"2021","journal-title":"Stem Cell Res."},{"key":"B113","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.scr.2016.08.002","article-title":"Generation of a gene-corrected isogenic control cell line from an Alzheimer's disease patient Ipsc line carrying a A79v mutation in Psen1","volume":"17","author":"Pires","year":"2016","journal-title":"Stem Cell Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"103000","DOI":"10.1016\/j.scr.2022.103000","article-title":"Generation of a homozygous Abca7-knockout human Ipsc line using the Crispr\/Cas9 system","volume":"66","author":"Guan","year":"2023","journal-title":"Stem Cell Res."},{"key":"B115","volume-title":"Modeling Alzheimer Disease with iPSCs and Mouse Model for the Identification of Risk Factors, New Targets, and Potential Therapeutic Strategies","author":"Graziosi","year":"2021"},{"key":"B116","doi-asserted-by":"publisher","first-page":"100571","DOI":"10.1016\/j.xpro.2021.100571","article-title":"Generation and validation of Apoe knockout human Ipsc-derived cerebral organoids","volume":"2","author":"Martens","year":"2021","journal-title":"STAR Protoc."},{"key":"B117","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.neuron.2019.07.010","article-title":"A large panel of isogenic App and Psen1 mutant human Ipsc neurons reveals shared endosomal abnormalities mediated by App B-Ctfs, Not A\u03b2","volume":"104","author":"Kwart","year":"2019","journal-title":"Neuron."},{"key":"B118","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/2096595819896178","article-title":"The application of patient-derived induced pluripotent stem cells for modeling and treatment of Alzheimer's disease","volume":"5","author":"Han","year":"2019","journal-title":"Brain Sci Adv."},{"key":"B119","doi-asserted-by":"publisher","first-page":"114982","DOI":"10.1016\/j.celrep.2024.114982","article-title":"Microglial Apoe3 Christchurch protects neurons from Tau pathology in a human Ipsc-based model of Alzheimer's disease","volume":"43","author":"Sun","year":"2024","journal-title":"Cell Rep."},{"key":"B120","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1021\/acssensors.3c02167","article-title":"Crispr-powered Aptasensor for diagnostics of Alzheimer's disease","volume":"9","author":"Jia","year":"2023","journal-title":"ACS Sens."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.neuron.2019.03.004","article-title":"Circuit mechanisms of Parkinson's disease","volume":"101","author":"McGregor","year":"2019","journal-title":"Neuron."},{"key":"B122","doi-asserted-by":"publisher","first-page":"435928","DOI":"10.3389\/fnins.2019.00552","article-title":"Prion-like mechanisms in Parkinson's disease","volume":"13","author":"Ma","year":"2019","journal-title":"Front Neurosci."},{"key":"B123","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/humu.21277","article-title":"Genetic etiology of Parkinson disease associated with mutations in the Snca, Park2, Pink1, Park7, and Lrrk2 genes: a mutation update","volume":"31","author":"Nuytemans","year":"2010","journal-title":"Hum Mutat."},{"key":"B124","doi-asserted-by":"publisher","first-page":"486","DOI":"10.2174\/1389202914666131210195808","article-title":"Genetic insights into sporadic Parkinson's disease pathogenesis","volume":"14","author":"Chai","year":"2013","journal-title":"Curr Genom."},{"key":"B125","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s00415-025-13030-2","article-title":"Global trends and projections of Parkinson's disease incidence: a 30-year analysis using Gbd 2021 data","volume":"272","author":"Xu","year":"2025","journal-title":"J Neurol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41583-024-00812-2","article-title":"Key genes and convergent pathogenic mechanisms in Parkinson disease","volume":"25","author":"Coukos","year":"2024","journal-title":"Nat Rev Neurosci."},{"key":"B127","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the A-Synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/mds.27193","article-title":"Neuropathology of genetic synucleinopathies with Parkinsonism: review of the literature","volume":"32","author":"Schneider","year":"2017","journal-title":"Mov Disord."},{"key":"B129","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","article-title":"Differential effects of severe vs mild Gba mutations on Parkinson disease","volume":"84","author":"Gan-Or","year":"2015","journal-title":"Neurology."},{"key":"B130","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/ana.24781","article-title":"Specifically Neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's","volume":"80","author":"Liu","year":"2016","journal-title":"Ann Neurol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev-pathmechdis-031521-034145","article-title":"Genetics and pathogenesis of Parkinson's syndrome","volume":"18","author":"Ye","year":"2023","journal-title":"Annu Rev Pathol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"101618","DOI":"10.1016\/j.arr.2022.101618","article-title":"Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson's disease","volume":"78","author":"Kip","year":"2022","journal-title":"Ageing Res Rev."},{"key":"B133","doi-asserted-by":"publisher","first-page":"e59252","DOI":"10.1371\/journal.pone.0059252","article-title":"Derivation and expansion using only small molecules of human neural progenitors for neurodegenerative disease modeling","volume":"8","author":"Reinhardt","year":"2013","journal-title":"PLoS ONE."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3390\/pharmaceutics14061252","article-title":"Crispr-Cas9-based technology and its relevance to gene editing in Parkinson's disease","volume":"14","author":"Rahman","year":"2022","journal-title":"Pharmaceutics."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1042\/BST20120138","article-title":"Link between Lrrk2, Autophagy and Naadp-mediated endolysosomal calcium signalling","volume":"40","author":"Gomez-Suaga","year":"2012","journal-title":"Biochem Soc Trans."},{"key":"B136","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1021\/acschembio.7b00657","article-title":"Crispri and Crispra screens in mammalian cells for precision biology and medicine","volume":"13","author":"Kampmann","year":"2018","journal-title":"ACS Chem Biol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1089\/crispr.2021.0025","article-title":"Crispr-Cas9 gene editing protects from the A53t-Snca overexpression-induced pathology of Parkinson's disease in vivo","volume":"5","author":"Yoon","year":"2022","journal-title":"CRISPR J."},{"key":"B138","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41434-023-00414-0","article-title":"Crispr\/Sgrna-directed synergistic activation mediator (Sam) as a therapeutic tool for Parkinson' S disease","volume":"31","author":"Narv\u00e1ez-P\u00e9rez","year":"2024","journal-title":"Gene Ther."},{"key":"B139","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40824-023-00381-y","article-title":"Crispr\/Cas9 assisted stem cell therapy in Parkinson's disease","volume":"27","author":"Pinjala","year":"2023","journal-title":"Biomater Res."},{"key":"B140","doi-asserted-by":"publisher","first-page":"102114","DOI":"10.1016\/j.arr.2023.102114","article-title":"Exploring Parkinson-associated Kinases for Crispr\/Cas9-based gene editing: beyond Alpha-Synuclein","volume":"92","author":"Mansour","year":"2023","journal-title":"Ageing Res Rev."},{"key":"B141","doi-asserted-by":"publisher","first-page":"102084","DOI":"10.1016\/j.omtn.2023.102084","article-title":"Neuronal-type-specific epigenome editing to decrease snca expression: implications for precision medicine in synucleinopathies","volume":"35","author":"Sun","year":"2024","journal-title":"Mol Ther Nucleic Acids."},{"key":"B142","volume-title":"Characterization of a PINK1 Knockout Model in THP-1 Cell Line Generated Using CRISPR\/Cas9","author":"Baez-Llovio","year":"2024"},{"key":"B143","volume-title":"Application of the CRISPR-Cas9 Genome Editing Approach for the Correction of the p.Gly2019Ser (c.6055G>A) LRRK2 Variant in Parkinson Disease","author":"Beligni","year":"2022"},{"key":"B144","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1038\/s41598-020-60273-2","article-title":"In vitro Crispr\/Cas9-directed gene editing to model Lrrk2 G2019s Parkinson's disease in common marmosets","volume":"10","author":"Vermilyea","year":"2020","journal-title":"Sci Rep."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1420183","DOI":"10.3389\/fbioe.2024.1420183","article-title":"Assessment of Crispra-mediated Gdnf overexpression in an in vitro Parkinson's disease model","volume":"12","author":"Guzm\u00e1n-Sastoque","year":"2024","journal-title":"Front Bioeng Biotechnol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"12420","DOI":"10.1038\/s41598-018-30436-3","article-title":"Crispr\/Cas9-mediated generation of Guangxi Bama Minipigs harboring three mutations in A-Synuclein causing Parkinson's disease","volume":"8","author":"Zhu","year":"2018","journal-title":"Sci Rep."},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1101\/2023.09.05.556425","article-title":"Robust nuclease-dead S. Aureus Dcas9-mediated alpha-synuclein knockdown in substantia nigra in a humanized mouse model of Parkinson's disease","author":"Torres","year":"2023","journal-title":"bioRxiv."},{"key":"B148","doi-asserted-by":"publisher","first-page":"eabg4574","DOI":"10.1126\/sciadv.abg4574","article-title":"Loss of Uchl1 rescues the defects related to Parkinson's disease by suppressing glycolysis","volume":"7","author":"Ham","year":"2021","journal-title":"Sci Adv."},{"key":"B149","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41586-021-04059-0","article-title":"Disruption of mitochondrial complex I induces progressive Parkinsonism","volume":"599","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2021","journal-title":"Nature."},{"key":"B150","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1093\/hmg\/ddw279","article-title":"Impaired striatal dopamine release in homozygous Vps35 D620n knock-in mice","volume":"25","author":"Ishizu","year":"2016","journal-title":"Hum Mol Genet."},{"key":"B151","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41589-020-00734-x","article-title":"Phospholipase Ipla2\u03b2 averts ferroptosis by eliminating a Redox lipid death signal","volume":"17","author":"Sun","year":"2021","journal-title":"Nat Chem Biol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/33416","article-title":"Mutations in the Parkin gene cause autosomal recessive juvenile Parkinsonism","volume":"392","author":"Kitada","year":"1998","journal-title":"Nature."},{"key":"B153","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/j.1471-4159.2009.06350.x","article-title":"Absence of nigral degeneration in aged Parkin\/Dj-1\/Pink1 triple knockout mice","volume":"111","author":"Kitada","year":"2009","journal-title":"J Neurochem."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/ng.485","article-title":"Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease","volume":"41","author":"Satake","year":"2009","journal-title":"Nat Genet."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/ng.487","article-title":"Genome-wide association study reveals genetic risk underlying Parkinson's disease","volume":"41","author":"Sim\u00f3n-S\u00e1nchez","year":"2009","journal-title":"Nat Genet."},{"key":"B156","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(10)62345-8","article-title":"Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"377","author":"Consortium","year":"2011","journal-title":"Lancet."},{"key":"B157","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11557","article-title":"Progressive Degeneration of Human Neural Stem Cells Caused by Pathogenic Lrrk2","volume":"491","author":"Liu","year":"2012","journal-title":"Nature."},{"key":"B158","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.stem.2016.08.002","article-title":"Functional impairment in miro degradation and mitophagy is a shared feature in familial and sporadic Parkinson's disease","volume":"19","author":"Hsieh","year":"2016","journal-title":"Cell Stem Cell."},{"key":"B159","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1083\/jcb.200809125","article-title":"Parkin is recruited selectively to impaired mitochondria and promotes their autophagy","volume":"183","author":"Narendra","year":"2008","journal-title":"J Cell Biol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-6606-5-35","article-title":"Mitochondrial dysfunction associated with increased oxidative stress and A-Synuclein accumulation in Park2 Ipsc-derived neurons and postmortem brain tissue","volume":"5","author":"Imaizumi","year":"2012","journal-title":"Mol Brain."},{"key":"B161","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1093\/brain\/awaa279","article-title":"Mitochondrial Uqcrc1 mutations cause autosomal dominant Parkinsonism with polyneuropathy","volume":"143","author":"Lin","year":"2020","journal-title":"Brain."},{"key":"B162","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1186\/s13287-025-04660-4","article-title":"Three-Dimensional midbrain organoids: a next-generation tool for Parkinson's disease modelling and drug discovery","volume":"16","author":"Elvira","year":"2025","journal-title":"Stem Cell Res Ther."},{"key":"B163","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ymeth.2021.04.023","article-title":"Alleviation of neurological disease by Rna editing","volume":"194","author":"Zhang","year":"2021","journal-title":"Methods."},{"key":"B164","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3233\/JHD-160222","article-title":"Modern genome editing technologies in Huntington's disease research","volume":"6","author":"Malankhanova","year":"2017","journal-title":"J Huntingt Dis."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10048-025-00801-2","article-title":"Neuroinflammation and neurodegeneration in Huntington's disease: genetic hallmarks, role of metals and organophosphates","volume":"26","author":"Kunwar","year":"2025","journal-title":"Neurogenetics."},{"key":"B166","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/brainsci10010043","article-title":"Therapeutic advances for Huntington's disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Brain Sci."},{"key":"B167","doi-asserted-by":"publisher","first-page":"a024240","DOI":"10.1101\/cshperspect.a024240","article-title":"Huntington's disease: mechanisms of pathogenesis and therapeutic strategies","volume":"7","author":"Jimenez-Sanchez","year":"2017","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.4103\/1673-5374.390969","article-title":"Therapeutic advances in neural regeneration for Huntington's disease","volume":"19","author":"D'Egidio","year":"2024","journal-title":"Neural Regen Res."},{"key":"B169","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40035-016-0065-1","article-title":"Dysregulation of autophagy and mitochondrial function in Parkinson's disease","volume":"5","author":"Wang","year":"2016","journal-title":"Transl Neurodegener."},{"key":"B170","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.3390\/pharmaceutics14122657","article-title":"Mitochondrial dysfunction: pathophysiology and mitochondria-targeted drug delivery approaches","volume":"14","author":"Khan","year":"2022","journal-title":"Pharmaceutics."},{"key":"B171","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/mds.29228","article-title":"Prevalence and incidence of Huntington's disease: an updated systematic review and meta-analysis","volume":"37","author":"Medina","year":"2022","journal-title":"Mov Disord."},{"key":"B172","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.3390\/ijms25073845","article-title":"Huntington's disease: complex pathogenesis and therapeutic strategies","volume":"25","author":"Tong","year":"2024","journal-title":"Int J Mol Sci."},{"key":"B173","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1111\/j.1460-9568.2008.06310.x","article-title":"Mechanisms of neurodegeneration in Huntington's disease","volume":"27","author":"Gil","year":"2008","journal-title":"Eur J Neurosci."},{"key":"B174","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","article-title":"Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities","volume":"16","author":"Tabrizi","year":"2020","journal-title":"Nat Rev Neurol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.tibs.2013.05.003","article-title":"Huntington's disease: underlying molecular mechanisms and emerging concepts","volume":"38","author":"Labbadia","year":"2013","journal-title":"Trends Biochem Sci."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1364742","DOI":"10.3389\/fgene.2024.1364742","article-title":"Application and perspective of Crispr\/Cas9 genome editing technology in human diseases modeling and gene therapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Genet."},{"key":"B178","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.tins.2023.02.005","article-title":"The potential of gene editing for Huntington's disease","volume":"46","author":"Duan","year":"2023","journal-title":"Trends Neurosci."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s12264-022-00880-3","article-title":"Crispr-based genome-editing tools for Huntington's disease research and therapy","volume":"38","author":"Qin","year":"2022","journal-title":"Neurosci Bull."},{"key":"B180","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12033-023-00724-z","article-title":"An update on the application of Crispr technology in clinical practice","volume":"66","author":"Morshedzadeh","year":"2024","journal-title":"Mol Biotechnol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1093\/hmg\/ddw286","article-title":"Permanent inactivation of Huntington's disease mutation by personalized Allele-Specific Crispr\/Cas9","volume":"25","author":"Shin","year":"2016","journal-title":"Hum Mol Genet."},{"key":"B182","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1172\/JCI92087","article-title":"Crispr\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease","volume":"127","author":"Yang","year":"2017","journal-title":"J Clin Invest."},{"key":"B183","doi-asserted-by":"publisher","first-page":"e0204735","DOI":"10.1371\/journal.pone.0204735","article-title":"Introducing an expanded Cag tract into the Huntingtin gene causes a wide spectrum of ultrastructural defects in cultured human cells","volume":"13","author":"Morozova","year":"2018","journal-title":"PLoS ONE"},{"key":"B184","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.3390\/ijms21051854","article-title":"Generation of new isogenic models of Huntington's disease using Crispr-Cas9 technology","volume":"21","author":"Dabrowska","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B185","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fnins.2018.00075","article-title":"Precise excision of the Cag tract from the Huntingtin gene by Cas9 Nickases","volume":"12","author":"Dabrowska","year":"2018","journal-title":"Front Neurosci."},{"key":"B186","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","article-title":"Crispr\/Cas9 editing of the mutant Huntingtin Allele in vitro and in vivo","volume":"25","author":"Monteys","year":"2017","journal-title":"Mol Ther."},{"key":"B187","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","article-title":"Crispr-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington's disease mouse model","volume":"17","author":"Ekman","year":"2019","journal-title":"Mol Ther Nucleic Acids."},{"key":"B188","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s42003-023-04829-8","article-title":"DNA double-strand break-free crispr interference delays Huntington's disease progression in mice","volume":"6","author":"Seo","year":"2023","journal-title":"Commun Biol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13024-024-00794-w","article-title":"Rna-targeting Crispr\/Casrx system relieves disease symptoms in Huntington's disease models","volume":"20","author":"Lin","year":"2025","journal-title":"Mol Neurodegener."},{"key":"B190","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s42003-021-02304-w","article-title":"Precise Cag repeat contraction in a Huntington's disease mouse model is enabled by gene editing with Spcas9-Ng","volume":"4","author":"Oura","year":"2021","journal-title":"Commun Biol."},{"key":"B191","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1016\/j.celrep.2017.08.075","article-title":"The self-inactivating Kamicas9 system for the editing of Cns disease genes","volume":"20","author":"Merienne","year":"2017","journal-title":"Cell Rep."},{"key":"B192","doi-asserted-by":"publisher","first-page":"e141042","DOI":"10.1172\/jci.insight.141042","article-title":"Allele-specific silencing of the gain-of-function mutation in Huntington's disease using Crispr\/Cas9","volume":"7","author":"Shin","year":"2022","journal-title":"JCI Insight."},{"key":"B193","doi-asserted-by":"publisher","first-page":"eadn4600","DOI":"10.1126\/scitranslmed.adn4600","article-title":"Antisense Oligonucleotide\u2013mediated Msh3 suppression reduces somatic Cag repeat expansion in Huntington's disease Ipsc\u2013derived striatal neurons","volume":"17","author":"Bunting","year":"2025","journal-title":"Sci Transl Med."},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.05.602282","article-title":"In vivo Crispr base editing for treatment of Huntington's disease","author":"Shirguppe","year":"2024","journal-title":"bioRxiv."},{"key":"B195","volume-title":"Huntingtin CAG Repeat Expansions in Induced Pluripotent Stem Cell Models of Huntington's Disease.","author":"Donaldson","year":"2019"},{"key":"B196","doi-asserted-by":"publisher","first-page":"16","DOI":"10.12703\/r\/11-16","article-title":"Huntington's disease Ipsc models\u2014using human patient cells to understand the pathology caused by expanded cag repeats","volume":"11","author":"Kaye","year":"2022","journal-title":"Faculty Rev."},{"key":"B197","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.stemcr.2017.01.022","article-title":"Reversal of phenotypic abnormalities by Crispr\/Cas9-mediated gene correction in Huntington disease patient-derived induced pluripotent stem cells","volume":"8","author":"Xu","year":"2017","journal-title":"Stem Cell Rep."},{"key":"B198","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41398-021-01605-2","article-title":"Crispr\/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar Ataxia type 3 patient-derived induced pluripotent stem cells","volume":"11","author":"He","year":"2021","journal-title":"Transl Psychiatry."},{"key":"B199","doi-asserted-by":"publisher","first-page":"576592","DOI":"10.3389\/fcell.2020.576592","article-title":"Mitochondrial and redox modifications in Huntington disease induced pluripotent stem cells rescued by Crispr\/Cas9 Cags targeting","volume":"8","author":"Lopes","year":"2020","journal-title":"Front Cell Dev Biol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41593-022-01207-1","article-title":"An Rna-targeting Crispr\u2013Cas13d system alleviates disease-related phenotypes in Huntington's disease models","volume":"26","author":"Morelli","year":"2023","journal-title":"Nat Neurosci."},{"key":"B201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.71","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"B202","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.irn.2024.04.011","article-title":"Amyotrophic lateral sclerosis; clinical features, differential diagnosis and pathology","volume":"176","author":"Van","year":"2024","journal-title":"Int Rev Neurobiol."},{"key":"B204","doi-asserted-by":"publisher","first-page":"e613","DOI":"10.1212\/WNL.0000000000207474","article-title":"Global prevalence and incidence of amyotrophic lateral sclerosis: a systematic review","volume":"101","author":"Wolfson","year":"2023","journal-title":"Neurology."},{"key":"B205","doi-asserted-by":"publisher","first-page":"eabc9450","DOI":"10.1126\/sciadv.abc9450","article-title":"Crispr-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy","volume":"6","author":"Rosenblum","year":"2020","journal-title":"Sci Adv."},{"key":"B206","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded Ggggcc hexanucleotide repeat in noncoding region of C9orf72 causes chromosome 9p-Linked Ftd and Als","volume":"72","author":"DeJesus-Hernandez","year":"2011","journal-title":"Neuron."},{"key":"B207","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1126\/science.1154584","article-title":"Tdp-43 mutations in familial and sporadic amyotrophic lateral sclerosis","volume":"319","author":"Sreedharan","year":"2008","journal-title":"Science."},{"key":"B208","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1126\/science.1166066","article-title":"Mutations in the Fus\/Tls gene on chromosome 16 cause familial amyotrophic lateral sclerosis","volume":"323","author":"Kwiatkowski Jr","year":"2009","journal-title":"Science."},{"key":"B209","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Kiernan","year":"2011","journal-title":"Lancet."},{"key":"B210","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/nrn1971","article-title":"Molecular biology of amyotrophic lateral sclerosis: insights from genetics","volume":"7","author":"Pasinelli","year":"2006","journal-title":"Nat Rev Neurosci."},{"key":"B211","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1093\/hmg\/5.Supplement_1.1465","article-title":"Genetics of amyotrophic lateral sclerosis","volume":"5","author":"Siddique","year":"1996","journal-title":"Hum Mol Genet."},{"key":"B212","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/ene.14393","article-title":"Amyotrophic lateral sclerosis: a clinical review","volume":"27","author":"Masrori","year":"2020","journal-title":"Eur J Neurol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1474-4422(14)70233-9","article-title":"C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis","volume":"14","author":"Rohrer","year":"2015","journal-title":"Lancet Neurol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00401-011-0937-5","article-title":"Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9orf72 gene on Chromosome 9p","volume":"123","author":"Stewart","year":"2012","journal-title":"Acta Neuropathol."},{"key":"B215","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S1474-4422(08)70071-1","article-title":"Tardbp mutations in amyotrophic lateral sclerosis with Tdp-43 neuropathology: a genetic and histopathological analysis","volume":"7","author":"Van Deerlin","year":"2008","journal-title":"Lancet Neurol."},{"key":"B216","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/ana.21392","article-title":"Tdp-43 mutation in familial amyotrophic lateral sclerosis","volume":"63","author":"Yokoseki","year":"2008","journal-title":"Ann Neurol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/humu.22319","article-title":"Tardbp and Fus mutations associated with amyotrophic lateral sclerosis: summary and update","volume":"34","author":"Lattante","year":"2013","journal-title":"Hum Mutat."},{"key":"B218","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.3390\/cells9122687","article-title":"Pathogenic genome signatures that damage motor neurons in amyotrophic lateral sclerosis","volume":"9","author":"Yousefian-Jazi","year":"2020","journal-title":"Cells."},{"key":"B219","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fnmol.2020.00078","article-title":"Dysregulation of Rna-binding proteins in amyotrophic lateral sclerosis","volume":"13","author":"Xue","year":"2020","journal-title":"Front Mol Neurosci."},{"key":"B220","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/nan.12187","article-title":"Invited review: decoding the pathophysiological mechanisms that underlie Rna dysregulation in neurodegenerative disorders: a review of the current state of the art","volume":"41","author":"Walsh","year":"2015","journal-title":"Neuropathol Appl Neurobiol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"659610","DOI":"10.3389\/fmolb.2021.659610","article-title":"Comprehensive analysis of the role of Hnrnp A1 function and dysfunction in the pathogenesis of neurodegenerative disease","volume":"8","author":"Clarke","year":"2021","journal-title":"Front Mol Biosci."},{"key":"B222","doi-asserted-by":"publisher","first-page":"594975","DOI":"10.3389\/fncel.2020.594975","article-title":"The neglected genes of Als: cytoskeletal dynamics impact synaptic degeneration in Als","volume":"14","author":"Castellanos-Montiel","year":"2020","journal-title":"Front Cell Neurosci."},{"key":"B223","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40035-021-00272-z","article-title":"New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis","volume":"10","author":"Theunissen","year":"2021","journal-title":"Transl Neurodegener."},{"key":"B224","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3390\/ijms19030906","article-title":"Crispr\/Cas9 technology as an emerging tool for targeting amyotrophic lateral sclerosis (Als)","volume":"19","author":"Kruminis-Kaszkiel","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B225","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s42003-020-0755-1","article-title":"Crispr-mediated gene correction links the Atp7a M1311v mutations with amyotrophic lateral sclerosis pathogenesis in one individual","volume":"3","author":"Yun","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B226","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.3390\/ijms21113801","article-title":"Crispr\/Cas9-mediated gene correction to understand Als","volume":"21","author":"Yun","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B227","doi-asserted-by":"publisher","first-page":"eaar3952","DOI":"10.1126\/sciadv.aar3952","article-title":"In vivo genome editing improves motor function and extends survival in a mouse model of Als","volume":"3","author":"Gaj","year":"2017","journal-title":"Sci Adv."},{"key":"B228","doi-asserted-by":"publisher","first-page":"6286","DOI":"10.1038\/s41467-022-33332-7","article-title":"Crispr\/Cas9-mediated excision of Als\/Ftd-causing hexanucleotide repeat expansion in C9orf72 rescues major disease mechanisms in vivo and in vitro","volume":"13","author":"Meijboom","year":"2022","journal-title":"Nat Commun."},{"key":"B229","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s13238-017-0397-3","article-title":"Crispr\/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient Ipscs","volume":"8","author":"Wang","year":"2017","journal-title":"Protein Cell."},{"key":"B230","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.stemcr.2017.02.019","article-title":"Genetic correction of Sod1 mutant Ipscs reveals Erk and Jnk activated Ap1 as a driver of neurodegeneration in amyotrophic lateral sclerosis","volume":"8","author":"Bhinge","year":"2017","journal-title":"Stem Cell Rep."},{"key":"B231","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1093\/hmg\/ddaa106","article-title":"Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by Crispr\/Cas9 genome editing using homology-directed repair","volume":"29","author":"Ababneh","year":"2020","journal-title":"Hum Mol Genet."},{"key":"B232","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41434-019-0116-1","article-title":"The deletion of mutant Sod1 via Crispr\/Cas9\/Sgrna prolongs survival in an amyotrophic lateral sclerosis mouse model","volume":"27","author":"Duan","year":"2020","journal-title":"Gene Ther."},{"key":"B233","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.ymthe.2020.01.005","article-title":"Treatment of a mouse model of Als by in vivo base editing","volume":"28","author":"Lim","year":"2020","journal-title":"Mol Ther."},{"key":"B234","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.molmed.2013.11.003","article-title":"Tdp-43-Mediated neurodegeneration: towards a loss-of-function hypothesis?","volume":"20","author":"Broeck","year":"2014","journal-title":"Trends Mol Med."},{"key":"B235","doi-asserted-by":"publisher","first-page":"e1002214","DOI":"10.1371\/journal.pgen.1002214","article-title":"Fus and Tardbp but Not Sod1 interact in genetic models of amyotrophic lateral sclerosis","volume":"7","author":"Kabashi","year":"2011","journal-title":"PLoS Genet."},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1101\/051193","article-title":"Crispr-Cas9 targeted deletion of the C9orf72 repeat expansion mutation corrects cellular phenotypes in patient-derived Ips cells","author":"Pribadi","year":"2016","journal-title":"bioRxiv."},{"key":"B237","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41467-017-02729-0","article-title":"C9orf72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable Ampa receptor-mediated excitotoxicity","volume":"9","author":"Selvaraj","year":"2018","journal-title":"Nat Commun."},{"key":"B238","doi-asserted-by":"publisher","first-page":"9628","DOI":"10.1073\/pnas.1901313116","article-title":"Partial inhibition of the overactivated Ku80-dependent DNA repair pathway rescues neurodegeneration in C9orf72-Als\/Ftd","volume":"116","author":"Lopez-Gonzalez","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"key":"B239","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.stemcr.2020.01.010","article-title":"Knocking out C9orf72 exacerbates axonal trafficking defects associated with hexanucleotide repeat expansion and reduces levels of heat shock proteins","volume":"14","author":"Abo-Rady","year":"2020","journal-title":"Stem Cell Rep."},{"key":"B240","doi-asserted-by":"publisher","first-page":"380","DOI":"10.14336\/AD.2015.0506","article-title":"Mechanisms of muscle denervation in aging: insights from a mouse model of amyotrophic lateral sclerosis","volume":"6","author":"Park","year":"2015","journal-title":"Aging Dis."},{"key":"B241","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1056\/NEJM199412223312516","article-title":"Transgenic-mouse model of amyotrophic lateral sclerosis","volume":"331","author":"Gurney","year":"1994","journal-title":"N Engl J Med."},{"key":"B242","doi-asserted-by":"publisher","first-page":"fcab223","DOI":"10.1093\/braincomms\/fcab223","article-title":"Midbrain organoids with an Snca gene triplication model key features of synucleinopathy","volume":"3","author":"Mohamed","year":"2021","journal-title":"Brain Commun."},{"key":"B243","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/ijms25021050","article-title":"Delivery of adeno-associated virus vectors to the central nervous system for correction of single gene disorders","volume":"25","author":"Daci","year":"2024","journal-title":"Int J Mol Sci."},{"key":"B244","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/17425247.2016.1178237","article-title":"Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases","volume":"13","author":"Cacciatore","year":"2016","journal-title":"Expert Opin Drug Deliv."},{"key":"B245","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1007\/s12033-023-00932-7","article-title":"Exosomes for Crispr-Cas9 delivery: the cutting edge in genome editing","volume":"66","author":"Aslan","year":"2024","journal-title":"Mol Biotechnol."},{"key":"B246","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/scipharm87010006","article-title":"Overcoming the blood\u2013brain barrier. Challenges and tricks for Cns drug delivery","volume":"87","author":"Bors","year":"2019","journal-title":"Sci Pharm."},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.4983","article-title":"Building Crispr gene therapies for the central nervous system: a review","author":"Salomonsson","year":"2024","journal-title":"JAMA Neurol."},{"key":"B248","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering Crispr: a review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv."},{"key":"B249","doi-asserted-by":"publisher","first-page":"eabm8011","DOI":"10.1126\/sciadv.abm8011","article-title":"Blood-brain barrier\u2013penetrating single Crispr-Cas9 nanocapsules for effective and safe glioblastoma gene therapy","volume":"8","author":"Zou","year":"2022","journal-title":"Sci Adv."},{"key":"B250","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.neuro.2011.12.009","article-title":"Barriers in the developing brain and neurotoxicology","volume":"33","author":"Ek","year":"2012","journal-title":"Neurotoxicology."},{"key":"B251","doi-asserted-by":"publisher","first-page":"104694","DOI":"10.1016\/j.jddst.2023.104694","article-title":"Strategies facilitating the permeation of nanoparticles through blood-brain barrier: an insight towards the development of brain-targeted drug delivery system","volume":"86","author":"Mishra","year":"2023","journal-title":"J Drug Deliv Sci Technol."},{"key":"B252","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/pharmaceutics12090801","article-title":"Crispr\/Cas9 delivery potentials in Alzheimer's disease management: a mini review","volume":"12","author":"Hanafy","year":"2020","journal-title":"Pharmaceutics."},{"key":"B253","doi-asserted-by":"publisher","first-page":"e2400374","DOI":"10.1002\/adbi.202400374","article-title":"Vectors in Crispr gene editing for neurological disorders: challenges and opportunities","volume":"9","author":"Xiong","year":"2025","journal-title":"Adv Biol."},{"key":"B254","doi-asserted-by":"publisher","first-page":"895713","DOI":"10.3389\/fbioe.2022.895713","article-title":"Viral vectors for the in vivo delivery of Crispr components: advances and challenges","volume":"10","author":"Asmamaw Mengstie","year":"2022","journal-title":"Front Bioeng Biotechnol."},{"key":"B255","doi-asserted-by":"publisher","first-page":"103652","DOI":"10.1016\/j.drudis.2023.103652","article-title":"Crispr-Cas9 in Alzheimer's disease: therapeutic trends, modalities, and challenges","volume":"28","author":"Chacko","year":"2023","journal-title":"Drug Discov Today."},{"key":"B256","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1089\/hum.2015.069","article-title":"Challenges in Crispr\/Cas9 delivery: potential roles of nonviral vectors","volume":"26","author":"Li","year":"2015","journal-title":"Hum Gene Ther."},{"key":"B257","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields Aav variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat Biotechnol."},{"key":"B258","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered Aavs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat Neurosci."},{"key":"B259","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ymeth.2021.06.004","article-title":"Latest progress in the study of nanoparticle-based delivery of the Crispr\/Cas9 system","volume":"194","author":"Yu","year":"2021","journal-title":"Methods."},{"key":"B260","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.2147\/IJN.S457393","article-title":"Advancing CNS therapeutics: enhancing neurological disorders with nanoparticle-based gene and enzyme replacement therapies","volume":"20","author":"Liu","year":"2025","journal-title":"Int J Nanomed."},{"key":"B261","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-1-0716-1617-8_5","article-title":"Modification of nanoparticles with transferrin for targeting brain tissues","volume-title":"Peptide Conjugation: Methods and Protocols.","author":"Attia","year":"2021"},{"key":"B262","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/pharmaceutics14030672","article-title":"Strategies for targeted delivery of exosomes to the brain: advantages and challenges","volume":"14","author":"Choi","year":"2022","journal-title":"Pharmaceutics."},{"key":"B263","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1021\/acs.biochem.3c00371","article-title":"Lipid nanoparticles deliver Mrna to the brain after an intracerebral injection","volume":"62","author":"Tuma","year":"2023","journal-title":"Biochemistry."},{"key":"B264","doi-asserted-by":"publisher","first-page":"121959","DOI":"10.1016\/j.biomaterials.2022.121959","article-title":"Efficient in vivo neuronal genome editing in the mouse brain using nanocapsules containing Crispr-Cas9 ribonucleoproteins","volume":"293","author":"Metzger","year":"2023","journal-title":"Biomaterials."},{"key":"B265","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.2174\/1568026620666201023122903","article-title":"Peptide shuttle-mediated delivery for brain gene therapies","volume":"20","author":"Garcia","year":"2020","journal-title":"Curr Top Med Chem."},{"key":"B266","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.1039\/D2BM00368F","article-title":"Development of non-viral vectors for neuronal-targeted delivery of Crispr-Cas9 Rna-proteins as a therapeutic strategy for neurological disorders","volume":"10","author":"Shalaby","year":"2022","journal-title":"Biomater Sci."},{"key":"B267","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.3390\/nano13233004","article-title":"Recent uses of lipid nanoparticles, cell-penetrating and bioactive peptides for the development of brain-targeted nanomedicines against neurodegenerative disorders","volume":"13","author":"Wu","year":"2023","journal-title":"Nanomaterials."},{"key":"B268","doi-asserted-by":"publisher","first-page":"1143157","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in Crispr\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front Bioeng Biotechnol."},{"key":"B269","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.celrep.2014.09.044","article-title":"Enhanced specificity and efficiency of the Crispr\/Cas9 system with optimized sgRNA parameters in Drosophila","volume":"9","author":"Ren","year":"2014"},{"key":"B270","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"Rna-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science."},{"key":"B271","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1093\/nar\/gku109","article-title":"Direct activation of human and mouse Oct4 genes using engineered Tale and Cas9 transcription factors","volume":"42","author":"Hu","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B272","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nbt.2647","article-title":"DNA targeting specificity of Rna-Guided Cas9 nucleases","volume":"31","author":"Hsu","year":"2013","journal-title":"Nat Biotechnol."},{"key":"B273","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrg3686","article-title":"A guide to genome engineering with programmable nucleases","volume":"15","author":"Kim","year":"2014","journal-title":"Nat Rev Genet."},{"key":"B274","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target effects in Crispr\/Cas9-mediated genome engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"BioDesign Res."},{"key":"B275","doi-asserted-by":"publisher","first-page":"1902312","DOI":"10.1002\/advs.201902312","article-title":"Crispr\/Cas systems in genome editing: methodologies and tools for Sgrna design, off-target evaluation, and strategies to mitigate off-target effects","volume":"7","author":"Manghwar","year":"2020","journal-title":"Adv Sci."},{"key":"B276","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3390\/cells9071608","article-title":"Latest developed strategies to minimize the off-target effects in Crispr-Cas-mediated genome editing","volume":"9","author":"Naeem","year":"2020","journal-title":"Cells."},{"key":"B277","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/sj.gt.3303048","article-title":"Adeno-associated viral vector-mediated hypoxia-regulated Vegf gene transfer promotes angiogenesis following focal cerebral ischemia in mice","volume":"15","author":"Shen","year":"2008","journal-title":"Gene Ther."},{"key":"B278","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nbt.2808","article-title":"Improving Crispr-Cas nuclease specificity using truncated guide Rnas","volume":"32","author":"Fu","year":"2014","journal-title":"Nat Biotechnol."},{"key":"B279","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fpls.2019.00612","article-title":"Efficiency otimization of Crispr\/Cas9-mediated targeted mutagenesis in grape","volume":"10","author":"Ren","year":"2019","journal-title":"Front Plant Sci."},{"key":"B280","doi-asserted-by":"publisher","first-page":"7473","DOI":"10.1093\/nar\/gku402","article-title":"Crispr\/Cas9 systems have off-target activity with insertions or deletions between target DNA and Guide Rna sequences","volume":"42","author":"Lin","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B281","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nchembio.2559","article-title":"Partial DNA-Guided Cas9 enables genome editing with reduced off-target activity","volume":"14","author":"Yin","year":"2018","journal-title":"Nat Chem Biol."},{"key":"B282","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/s13238-019-0611-6","article-title":"Multiple Sgrnas facilitate base editing-mediated I-Stop to induce complete and precise gene disruption","volume":"10","author":"Jia","year":"2019","journal-title":"Protein Cell."},{"key":"B283","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0037-x","article-title":"Multiple Sgrnas with overlapping sequences enhance Crispr\/Cas9-mediated knock-in efficiency","volume":"50","author":"Jang","year":"2018","journal-title":"Exp Mol Med."},{"key":"B284","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity Crispr\u2013Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature."},{"key":"B285","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aad5227","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","author":"Slaymaker","year":"2016","journal-title":"Science."},{"key":"B286","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nature24268","article-title":"Enhanced proofreading governs Crispr\u2013Cas9 targeting accuracy","volume":"550","author":"Chen","year":"2017","journal-title":"Nature."},{"key":"B287","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1021\/acs.biochem.9b00573","article-title":"Off-target editing by Crispr-guided DNA base editors","volume":"58","author":"Park","year":"2019","journal-title":"Biochemistry."},{"key":"B288","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40259-023-00610-9","article-title":"Base editing and prime editing: potential therapeutic options for rare and common diseases","volume":"37","author":"Testa","year":"2023","journal-title":"BioDrugs."},{"key":"B289","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1134\/S0026893324010084","article-title":"Prime-editing methods and pegrna design programs","volume":"58","author":"Mikhaylova","year":"2024","journal-title":"Mol Biol."},{"key":"B290","doi-asserted-by":"publisher","first-page":"bbad530","DOI":"10.1093\/bib\/bbad530","article-title":"Crispr-Dipoff: an interpretable deep learning approach for Crispr Cas-9 Off-target prediction","volume":"25","author":"Toufikuzzaman","year":"2024","journal-title":"Brief Bioinform."},{"key":"B291","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-018-1459-4","article-title":"Deepcrispr: optimized Crispr guide Rna design by deep learning","volume":"19","author":"Chuai","year":"2018","journal-title":"Genome Biol."},{"key":"B292","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.1038\/s41596-021-00626-x","article-title":"Defining genome-wide Crispr\u2013Cas genome-editing nuclease activity with guide-Seq","volume":"16","author":"Malinin","year":"2021","journal-title":"Nat Protoc."},{"key":"B293","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/s41551-019-0431-2","article-title":"Immune-orthogonal orthologues of Aav Capsids and of Cas9 circumvent the immune response to the administration of gene therapy","volume":"3","author":"Moreno","year":"2019","journal-title":"Nat Biomed Eng."},{"key":"B294","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","article-title":"Aav-Crispr gene editing is negated by pre-existing immunity to Cas9","volume":"28","author":"Li","year":"2020","journal-title":"Mol Ther."},{"key":"B295","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.omtm.2018.06.006","article-title":"Prevalence of pre-existing antibodies to Crispr-associated nuclease Cas9 in the USA population","volume":"10","author":"Simhadri","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B296","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3390\/cells13100800","article-title":"Crispr-based gene therapies: from preclinical to clinical treatments","volume":"13","author":"Laurent","year":"2024","journal-title":"Cells."},{"key":"B297","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"Crispr-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med."},{"key":"B298","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med."},{"key":"B299","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.xphs.2019.10.003","article-title":"Immunogenicity of Cas9 protein","volume":"109","author":"Mehta","year":"2020","journal-title":"J Pharm Sci."},{"key":"B300","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat Med."},{"key":"B301","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ymthe.2020.05.007","article-title":"Immunity to Cas9 as an obstacle to persistent genome editing","volume":"28","author":"Gough","year":"2020","journal-title":"Mol Ther."},{"key":"B302","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1038\/s41467-018-05843-9","article-title":"Cas9 immunity creates challenges for Crispr gene editing therapies","volume":"9","author":"Crudele","year":"2018","journal-title":"Nat Commun."},{"key":"B303","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41551-018-0252-8","article-title":"Nanoparticle delivery of Crispr into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours","volume":"2","author":"Lee","year":"2018","journal-title":"Nat Biomed Eng."},{"key":"B304","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nbt.3055","article-title":"In vivo interrogation of gene function in the mammalian brain using Crispr-Cas9","volume":"33","author":"Swiech","year":"2015","journal-title":"Nat Biotechnol."},{"key":"B305","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3389\/fimmu.2014.00350","article-title":"Cell-mediated immunity to Aav vectors, evolving concepts and potential solutions","volume":"5","author":"Basner-Tschakarjan","year":"2014","journal-title":"Front Immunol."},{"key":"B306","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1208\/s12248-023-00814-5","article-title":"Evaluation of cellular immune response to Adeno-associated virus-based gene therapy","volume":"25","author":"Gorovits","year":"2023","journal-title":"AAPS J."},{"key":"B307","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/hum.2008.055","article-title":"Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral Capsid protein, limit transgene expression in mice","volume":"20","author":"Siders","year":"2009","journal-title":"Hum Gene Ther."},{"key":"B308","doi-asserted-by":"publisher","first-page":"13227","DOI":"10.1021\/acscatal.4c03278","article-title":"Structure of geobacillus stearothermophilus Cas9: insights into the catalytic process and thermostability of Crispr-Cas9","volume":"14","author":"Shen","year":"2024","journal-title":"ACS Catal."},{"key":"B309","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41467-024-55522-1","article-title":"Rational engineering of minimally immunogenic nucleases for gene therapy","volume":"16","author":"Raghavan","year":"2025","journal-title":"Nat Commun."},{"key":"B310","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1089\/crispr.2021.0142","article-title":"Reduction of pre-existing adaptive immune responses against Sacas9 in humans using epitope mapping and identification","volume":"5","author":"Shen","year":"2022","journal-title":"CRISPR J."},{"key":"B311","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1038\/s41467-019-09693-x","article-title":"Multifunctional Crispr-Cas9 with engineered immunosilenced human T cell epitopes","volume":"10","author":"Ferdosi","year":"2019","journal-title":"Nat Commun."},{"key":"B312","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41578-024-00725-7","article-title":"Crispr\u2013Cas9 delivery strategies for the modulation of immune and non-immune cells","volume":"10","author":"Alsaiari","year":"2025","journal-title":"Nat Rev Mater."},{"key":"B313","doi-asserted-by":"publisher","first-page":"1902575","DOI":"10.1002\/adma.201902575","article-title":"Fast and efficient Crispr\/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger Rna nanoparticles","volume":"31","author":"Liu","year":"2019","journal-title":"Adv Mater."},{"key":"B314","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1089\/crispr.2022.0051","article-title":"Advances in Crispr delivery methods: perspectives and challenges","volume":"5","author":"Demirci","year":"2022","journal-title":"CRISPR J."},{"key":"B315","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.omtn.2018.06.010","article-title":"Uridine depletion and chemical modification increase Cas9 Mrna activity and reduce immunogenicity without Hplc purification","volume":"12","author":"Vaidyanathan","year":"2018","journal-title":"Mol Ther Nucleic Acids."},{"key":"B316","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.omtn.2023.05.004","article-title":"The impact of nucleoside base modification in Mrna vaccine is influenced by the chemistry of its lipid nanoparticle delivery system","volume":"32","author":"Bernard","year":"2023","journal-title":"Mol Ther Nucleic Acids."},{"key":"B317","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2147\/CPAA.S418314","article-title":"Recent advances in messenger ribonucleic acid (Mrna) vaccines and their delivery systems: a review","volume":"15","author":"Yihunie","year":"2023","journal-title":"Clin Pharmacol Adv Appl."},{"key":"B318","doi-asserted-by":"publisher","first-page":"1127704","DOI":"10.3389\/fimmu.2023.1127704","article-title":"Immunomodulation\u2014a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system","volume":"14","author":"Strzelec","year":"2023","journal-title":"Front Immunol."},{"key":"B319","doi-asserted-by":"publisher","first-page":"1138596","DOI":"10.3389\/fbioe.2023.1138596","article-title":"Immunogenicity of Crispr therapeutics\u2014Critical considerations for clinical translation","volume":"11","author":"Ewaisha","year":"2023","journal-title":"Front Bioeng Biotechnol."},{"key":"B320","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3906\/biy-1912-52","article-title":"Bioethical issues in genome editing by Crispr-Cas9 technology","volume":"44","author":"Ayanoglu","year":"2020","journal-title":"Turk J Biol."},{"key":"B321","first-page":"45","article-title":"The development of new treatments for neurological disorders: insights, innovations, and ethical foundations","volume":"1","author":"Uyyala","year":"2023","journal-title":"Indus J Med Health Sci."},{"key":"B322","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/bmb\/ldx002","article-title":"Ethical issues of Crispr technology and gene editing through the lens of solidarity","volume":"122","author":"Mulvihill","year":"2017","journal-title":"Br Med Bull."},{"key":"B323","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.molmed.2015.05.006","article-title":"Germline genome-editing research and its socioethical implications","volume":"21","author":"Ishii","year":"2015","journal-title":"Trends Mol Med."},{"key":"B324","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bioe.12635","article-title":"Germline genome editing versus preimplantation genetic diagnosis: is there a case in favour of germline interventions?","volume":"34","author":"Ranisch","year":"2020","journal-title":"Bioethics."},{"key":"B325","volume-title":"Babies by Design: The Ethics of Genetic Choice","author":"Green","year":"2007"},{"key":"B326","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/d41586-019-00814-6","article-title":"Nih Pro germline editing moratorium","volume":"567","author":"Wolinetz","year":"2019","journal-title":"Nature."},{"key":"B327","volume-title":"Human Inheritable Genetic Modifications: Assessing Scientific, Ethical, Religious, and Policy Issues","author":"Frankel","year":"2000"},{"key":"B328","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2025.01.003","article-title":"Prenatal gene editing for neurodevelopmental diseases: ethical considerations","author":"Major","year":"2025","journal-title":"Am J Hum Genet."},{"key":"B329","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-658-46979-5_7","article-title":"Consequence arguments for and against germline editing","volume-title":"The Risks and Ethics of Human Gene Editing: A Philosophical Guide to the Arguments","author":"Hayenhjelm","year":"2025"},{"key":"B330","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.csbj.2020.03.014","article-title":"Ethical issues related to research on genome editing in human embryos","volume":"18","author":"Niemiec","year":"2020","journal-title":"Comput Struct Biotechnol J."},{"key":"B331","doi-asserted-by":"publisher","first-page":"e2004837117","DOI":"10.1073\/pnas.2004837117","article-title":"Setting ethical limits on human gene editing after the fall of the somatic\/germline barrier","volume":"118","author":"Evans","year":"2021","journal-title":"Proc Natl Acad Sci USA."},{"key":"B332","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ajhg.2017.06.012","article-title":"Human germline genome editing","volume":"101","author":"Ormond","year":"2017","journal-title":"Am J Hum Genet."},{"key":"B333","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11019-022-10115-x","article-title":"Initial heritable genome editing: mapping a responsible pathway from basic research to the clinic","volume":"26","author":"Ranisch","year":"2023","journal-title":"Med Health Care Philos."},{"key":"B334","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s40778-020-00179-x","article-title":"Responsible translational pathways for germline gene editing?","volume":"6","author":"Cwik","year":"2020","journal-title":"Curr Stem Cell Rep."},{"key":"B335","doi-asserted-by":"publisher","first-page":"E1105","DOI":"10.1001\/amajethics.2019.1105","article-title":"Genome editing, ethics, and politics","volume":"21","author":"Gabel","year":"2019","journal-title":"AMA J Ethics."},{"key":"B336","doi-asserted-by":"publisher","first-page":"103","DOI":"10.21775\/cimb.026.103","article-title":"Ethical issues regarding Crispr mediated genome editing","volume":"26","author":"Shinwari","year":"2018","journal-title":"Curr Issues Mol Biol."},{"key":"B337","doi-asserted-by":"publisher","first-page":"106161","DOI":"10.1016\/j.eplepsyres.2019.106161","article-title":"Somatic mutation: the hidden genetics of brain malformations and focal epilepsies","volume":"155","author":"Ye","year":"2019","journal-title":"Epilepsy Res."},{"key":"B338","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1057\/s41599-020-0416-5","article-title":"Gene editing and gender-specific medicine: a challenge for dementia research","volume":"6","author":"Zullo","year":"2020","journal-title":"Palgrave Commun."},{"key":"B339","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature."},{"key":"B340","doi-asserted-by":"publisher","first-page":"239","DOI":"10.59324\/ejmhr.2024.2(3).27","article-title":"Somatic genome editing: technical challenges and ethical appraisal","volume":"2","author":"O'Keeffe","year":"2024","journal-title":"Eur J Med Health Res."},{"key":"B341","doi-asserted-by":"publisher","first-page":"JE01","DOI":"10.7860\/JCDR\/2023\/68275.18809","article-title":"A scoping review on the ethical issues in the use of Crispr-Cas9 in the creation of human disease models","volume":"17","author":"D'souza","year":"2023","journal-title":"J Clin Diagn Res."},{"key":"B342","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11569-016-0259-0","article-title":"Crispr\/Cas9 genome editing\u2013new and old ethical issues arising from a revolutionary technology","volume":"10","author":"Baumann","year":"2016","journal-title":"Nanoethics."},{"key":"B343","doi-asserted-by":"publisher","first-page":"1000495","DOI":"10.3389\/fnsys.2022.1000495","article-title":"Brain augmentation and neuroscience technologies: current applications, challenges, ethics and future prospects","volume":"16","author":"Jangwan","year":"2022","journal-title":"Front Syst Neurosci."},{"key":"B344","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41586-021-03191-1","article-title":"The NIH somatic cell genome editing program","volume":"592","author":"Saha","year":"2021","journal-title":"Nature."},{"key":"B345","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s11948-018-0069-6","article-title":"Will Crispr germline engineering close the door to an open future?","volume":"25","author":"Mintz","year":"2019","journal-title":"Sci Eng Ethics."},{"key":"B346","first-page":"437","article-title":"A Crispr future for gene-editing regulation: a proposal for an updated biotechnology regulatory system in an Era of human genomic editing","volume":"87","author":"Tomlinson","year":"2018","journal-title":"Fordham L Rev."},{"key":"B347","first-page":"2","volume-title":"Who Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing: Report of the Fourth Meeting","year":"2021"},{"key":"B348","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jmb.2018.05.044","article-title":"Crispr ethics: moral considerations for applications of a powerful tool","volume":"431","author":"Brokowski","year":"2019","journal-title":"J Mol Biol."},{"key":"B349","year":"2017","journal-title":"Human Genome Editing: Science, Ethics, and Governance"},{"key":"B350","doi-asserted-by":"publisher","first-page":"p657","DOI":"10.1136\/bmj.p657","article-title":"Gene editing: China's new regulations contain concerning loopholes, experts warn","volume":"380","author":"Mahase","year":"2023","journal-title":"BMJ."},{"key":"B351","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/biolre\/ioac114","article-title":"Responsible governance of human germline genome editing in China","volume":"107","author":"Peng","year":"2022","journal-title":"Biol Reprod."},{"key":"B352","first-page":"107","article-title":"A new governance approach to regulating human genome editing","volume":"22","author":"Conley","year":"2020","journal-title":"North Carolina J Law Technol."},{"key":"B353","volume-title":"Creating Expectations: The Bioethics of Genetics as Reflected in Selected South African Media with Specific Reference to Crispr-Cas9","author":"Rademan","year":"2020"},{"key":"B354","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/scipol\/scae010","article-title":"Governing with public engagement: an anticipatory approach to human genome editing","volume":"51","author":"Barlevy","year":"2024","journal-title":"Sci Public Policy."},{"key":"B355","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/23299460.2021.1957579","article-title":"Toward anticipatory governance of human genome editing: a critical review of scholarly governance discourse","volume":"8","author":"Nelson","year":"2021","journal-title":"J Responsible Innov."},{"key":"B356","article-title":"Crispr in 2018: Coming to a Human near You","author":"Mullin","year":"2017","journal-title":"MIT Technology Review."},{"key":"B357","unstructured":"Trials\n              C\n            \n          \n          \n          2024"},{"key":"B358","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1093\/nar\/gkx309","article-title":"Cell-type-specific genome editing with a microrna-responsive Crispr\u2013Cas9 switch","volume":"45","author":"Hirosawa","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B359","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10238-024-01540-8","article-title":"Recent developments and future directions in point-of-care next-generation Crispr-based rapid diagnosis","volume":"25","author":"Hassan","year":"2025","journal-title":"Clin Exp Med."},{"key":"B360","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/17576180.2025.2459520","article-title":"Crispr in clinical diagnostics: bridging the gap between research and practice","volume":"17","author":"Lafi","year":"2025","journal-title":"Bioanalysis."},{"key":"B361","doi-asserted-by":"publisher","first-page":"7364","DOI":"10.3390\/ijms26157364","article-title":"Precision neuro-oncology in glioblastoma: Ai-guided Crispr editing and real-time multi-omics for genomic brain surgery","volume":"26","author":"\u015eerban","year":"2025","journal-title":"Int J Mol Sci."},{"key":"B362","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1146\/annurev-neuro-112723-023232","article-title":"From organoids to assembloids: experimental approaches to study human neuropsychiatric disorders","volume":"48","author":"Levy","year":"2025","journal-title":"Annu Rev Neurosci."},{"key":"B363","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3390\/cells14110842","article-title":"Brain organoids and assembloids\u2014from disease modeling to drug discovery","volume":"14","author":"Ajongbolo","year":"2025","journal-title":"Cells."},{"key":"B364","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1038\/s41598-019-40222-4","article-title":"Magnetically guided non-invasive Crispr-Cas9\/Grna delivery across blood-brain barrier to eradicate latent Hiv-1 infection","volume":"9","author":"Kaushik","year":"2019","journal-title":"Sci Rep."},{"key":"B365","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nature17939","article-title":"Parkinson-associated risk variant in distal enhancer of A-synuclein modulates target gene expression","volume":"533","author":"Soldner","year":"2016","journal-title":"Nature."},{"key":"B366","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.3390\/biomedicines11082275","article-title":"Brain-derived neurotrophic factor dysregulation as an essential pathological feature in Huntington's disease: mechanisms and potential therapeutics","volume":"11","author":"Speidell","year":"2023","journal-title":"Biomedicines."},{"key":"B367","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41434-022-00375-w","article-title":"In vivo genome editing using novel Aav-Php variants rescues motor function deficits and extends survival in a Sod1-Als mouse model","volume":"30","author":"Chen","year":"2023","journal-title":"Gene Ther."},{"key":"B368","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide Tofersen for Sod1 Als","volume":"387","author":"Miller","year":"2022","journal-title":"N Engl J Med."},{"key":"B369","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1007\/s12035-022-03150-5","article-title":"Crispr\/Cas9 mediated therapeutic approach in Huntington's disease","volume":"60","author":"Alkanli","year":"2023","journal-title":"Mol Neurobiol."},{"key":"B370","doi-asserted-by":"publisher","first-page":"439","DOI":"10.4172\/2161-0460.1000439","article-title":"The potential of Crispr\/Cas9 gene editing as a treatment strategy for Alzheimer's disease","volume":"8","author":"Rohn","year":"2018","journal-title":"J Alzheimers Dis Parkinsonism."},{"key":"B371","doi-asserted-by":"publisher","first-page":"1223747","DOI":"10.3389\/fnins.2023.1223747","article-title":"Development of Crispr Cas9, spin-off technologies and their application in model construction and potential therapeutic methods of Parkinson's disease","volume":"17","author":"Qu","year":"2023","journal-title":"Front Neurosci."},{"key":"B372","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.brainresbull.2018.08.003","article-title":"Ligand conjugation: an emerging platform for enhanced brain drug delivery","volume":"142","author":"Nabi","year":"2018","journal-title":"Brain Res Bull."},{"key":"B373","doi-asserted-by":"publisher","first-page":"NEURO","DOI":"10.1523\/ENEURO.0495-18.2019","article-title":"A neuron-optimized Crispr\/dCas9 activation system for robust and specific gene regulation","volume":"6","author":"Savell","year":"2019","journal-title":"eNeuro."},{"key":"B374","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/cells8010020","article-title":"Ipscs as a platform for disease modeling, drug screening, and personalized therapy in muscular dystrophies","volume":"8","author":"Ortiz-Vitali","year":"2019","journal-title":"Cells."},{"key":"B375","doi-asserted-by":"publisher","first-page":"e114760","DOI":"10.15252\/embj.2023114760","article-title":"Rna-based medicine: from molecular mechanisms to therapy","volume":"42","author":"Sparmann","year":"2023","journal-title":"EMBO J."},{"key":"B376","doi-asserted-by":"publisher","first-page":"12284","DOI":"10.3390\/ijms252212284","article-title":"Recent advances and prospects in Rna drug development","volume":"25","author":"Tani","year":"2024","journal-title":"Int J Mol Sci."},{"key":"B377","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/0023677221993895","article-title":"Base editing and prime editing in laboratory animals","volume":"56","author":"Caso","year":"2022","journal-title":"Lab Anim."},{"key":"B378","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"24","author":"Chen","year":"2023","journal-title":"Nat Rev Genet."},{"key":"B379","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.neuron.2018.05.008","article-title":"Apoe4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human Ipsc-derived brain cell types","volume":"98","author":"Lin","year":"2018","journal-title":"Neuron."},{"key":"B380","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3390\/brainsci13040642","article-title":"The Trem2 H157y variant influences microglial phagocytosis, polarization, and inflammatory cytokine release","volume":"13","author":"Fu","year":"2023","journal-title":"Brain Sci."},{"key":"B381","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jare.2021.07.001","article-title":"Crispr\/Cas9 gene editing: new hope for Alzheimer's disease therapeutics","volume":"40","author":"Bhardwaj","year":"2022","journal-title":"J Adv Res."},{"key":"B382","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3390\/antiox14070781","article-title":"Crispr\/Cas9 and Ipsc-based therapeutic approaches in Alzheimer's disease","volume":"14","author":"Raffaele","year":"2025","journal-title":"Antioxidants."},{"key":"B383","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41587-023-01758-z","article-title":"Efficient prime editing in mouse brain, liver and heart with dual Aavs","volume":"42","author":"Davis","year":"2024","journal-title":"Nat Biotechnol."},{"key":"B384","doi-asserted-by":"publisher","first-page":"e10378","DOI":"10.1002\/btm2.10378","article-title":"Current progress of cerebral organoids for modeling Alzheimer's disease origins and mechanisms","volume":"8","author":"Sreenivasamurthy","year":"2023","journal-title":"Bioeng Trans Med."},{"key":"B385","doi-asserted-by":"publisher","first-page":"102919","DOI":"10.1016\/j.scr.2022.102919","article-title":"Generation of patient-derived pluripotent stem cell-lines and Crispr modified isogenic controls with mutations in the Parkinson's associated Gba gene","volume":"64","author":"Chen","year":"2022","journal-title":"Stem Cell Res."},{"key":"B386","doi-asserted-by":"publisher","first-page":"eabb1540","DOI":"10.1126\/sciadv.abb1540","article-title":"Neurodevelopmental defects and neurodegenerative phenotypes in human brain organoids carrying Parkinson's disease-linked Dnajc6 mutations","volume":"7","author":"Wulansari","year":"2021","journal-title":"Sci Adv."},{"key":"B387","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/ph17060763","article-title":"Emerging perspectives on prime editor delivery to the brain","volume":"17","author":"BenDavid","year":"2024","journal-title":"Pharmaceuticals."},{"key":"B388","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","article-title":"Downregulation of Snca expression by targeted editing of DNA methylation: a potential strategy for precision therapy in Pd","volume":"26","author":"Kantor","year":"2018","journal-title":"Mol Ther."},{"key":"B389","doi-asserted-by":"publisher","first-page":"RP89782","DOI":"10.7554\/eLife.89782","article-title":"Base editing strategies to convert Cag to Caa diminish the disease-causing mutation in Huntington's disease","volume":"12","author":"Choi","year":"2024","journal-title":"eLife."},{"key":"B390","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1093\/nar\/gkae310","article-title":"Precise editing of pathogenic nucleotide repeat expansions in Ipscs using paired prime editor","volume":"52","author":"Hwang","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"B391","doi-asserted-by":"publisher","first-page":"101385","DOI":"10.1016\/j.arr.2021.101385","article-title":"Gene targeting techniques for Huntington's disease","volume":"70","author":"Fields","year":"2021","journal-title":"Ageing Res Rev."},{"key":"B392","doi-asserted-by":"publisher","DOI":"10.1101\/2025.06.24.661435","article-title":"Self-inactivating Aav-Crispr at different ages enables sustained amelioration of Huntington's disease deficits in Bac226q mice","author":"Dai","year":"2025","journal-title":"bioRxiv."},{"key":"B393","doi-asserted-by":"publisher","first-page":"109166","DOI":"10.1016\/j.isci.2024.109166","article-title":"Homozygous Als-linked mutations in Tardbp\/Tdp-43 lead to hypoactivity and synaptic abnormalities in human Ipsc-derived motor neurons","volume":"27","author":"L\u00e9pine","year":"2024","journal-title":"iScience."},{"key":"B394","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.stemcr.2017.12.018","article-title":"Isogenic Fus-Egfp Ipsc reporter lines enable quantification of fus stress granule pathology that is rescued by drugs inducing autophagy","volume":"10","author":"Marrone","year":"2018","journal-title":"Stem Cell Res."},{"key":"B395","doi-asserted-by":"publisher","first-page":"111508","DOI":"10.1016\/j.celrep.2022.111508","article-title":"Genome-wide Crispr screen reveals V-Atpase as a drug target to lower levels of Als protein Ataxin-2","volume":"41","author":"Kim","year":"2022","journal-title":"Cell Rep."},{"key":"B396","doi-asserted-by":"publisher","first-page":"e179016","DOI":"10.1172\/JCI179016","article-title":"Crispr\/Cas13d targeting suppresses repeat-associated non-Aug translation of C9orf72 hexanucleotide repeat Rna","volume":"134","author":"Liu","year":"2024","journal-title":"J Clin Invest."},{"key":"B397","doi-asserted-by":"publisher","first-page":"632522","DOI":"10.3389\/fnins.2021.632522","article-title":"In vivo genome editing therapeutic approaches for neurological disorders: where are we in the translational pipeline?","volume":"15","author":"Lubroth","year":"2021","journal-title":"Front Neurosci."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1737468\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:07:57Z","timestamp":1769519277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1737468\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":397,"alternative-id":["10.3389\/fneur.2025.1737468"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1737468","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"article-number":"1737468"}}